MTOR and cancer: In addition, from the identified pharmacogenomic biomarkers of CVM-1118, treating cancer patients carrying specific mutations that activate signaling pathways downstream of TRAP1, such as mTOR and AKT, is expected to have a greater drug response that can be further tested in future clinical trials.